Are all 5-HT3 receptor antagonists the same?
A number of 5-HT3 receptor antagonists are currently in clinical development as antiemetics. In this paper we focus on two of these antagonists, granisetron and ondansetron, and compare their antimetic activity against cisplatin (10 mg/kg i.v.)- or whole body X-irradiation (200 rads)-induced emesis in the conscious ferret. The results presented here have been discussed in the light of the recently published literature. Our data suggest that in comparison to ondansetron, granisetron is a more potent, longer acting and pharmacologically "cleaner" compound with a more conventional dose-response profile. The possible impact of these features upon the performance of these compounds in the clinic is discussed particularly with respect to dosing regimens and clinical efficacy. Differences appear to be emerging between granisetron and ondansetron in both these respects, although a direct head-to-head clinical comparison has yet to be carried out. This would involve studies monitoring a sufficiently high number of patients receiving severely emetogenic regimes to allow real clinical differences to be detected with the appropriate statistical power.
Andrews
P L
PL
St. George's Hospital Medical School, Tooting, London, U.K.
Bhandari
P
P
Davey
P T
PT
Bingham
S
S
Marr
H E
HE
Blower
P R
PR
D000818:Animals; D000932:Antiemetics / Q000627:therapeutic use*; D002945:Cisplatin; D004305:Dose-Response Relationship, Drug; D005289:Ferrets; D017829:Granisetron; D007093:Imidazoles / Q000627:therapeutic use*; D007191:Indazoles / Q000627:therapeutic use*; D017294:Ondansetron; D012702:Serotonin Antagonists; D014839:Vomiting / Q000209:etiology / Q000517:prevention & control*; D014916:Whole-Body Irradiation
D000932:Antiemetics; D002945:Cisplatin; D017829:Granisetron; D007093:Imidazoles; D007191:Indazoles; D017294:Ondansetron; D012702:Serotonin Antagonists